NASDAQ:SLNO
Soleno Therapeutics Inc Stock News
$45.94
+0.82 (+1.82%)
At Close: May 06, 2024
Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome
08:00am, Friday, 05'th Feb 2021
Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints Recent analysis of
Soleno Therapeutics: Could Be Big Fish In The Small Pond
02:56pm, Friday, 08'th Jan 2021
Soleno Therapeutics is currently developing Diazoxide Choline Controlled-Release tablets and has a distinctive advantage in how well-documented the safety profile of DCCR's parent molecule, Diazoxide,
Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
08:00am, Monday, 04'th Jan 2021
REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatm
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
08:30am, Friday, 11'th Dec 2020
Soleno intends to submit plans to FDA to conduct further analyses of clinical data from completed and ongoing studies of DCCR, together with external, natural history studies Soleno intends to submit
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
04:01pm, Tuesday, 10'th Nov 2020
REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatm
REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatm
